her-2 icd peptide
Vaccineexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2000 (NCT00005956)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- her-2 icd peptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01922921 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2014 | National Cancer Institute (NCI), University of Washington |
| NCT00363012 | N/A | Apr 1, 2006 | National Cancer Institute (NCI), University of Washington |
| NCT00343109 | Phase 2 | Mar 1, 2004 | National Cancer Institute (NCI), University of Washington |
| NCT00005956 | N/A | Feb 1, 2000 | Duke University, National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 4 | 0 | 2 | 2000 |
| University of Washington | Academic/Hospital | 3 | 3 | 2 | 2004 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2000 |
3 organizations
Page 1 / 1